Research has shown that IL-17A promotes tumor progression through various mechanisms, including enhancing cell proliferation, inhibiting apoptosis and autophagy, recruiting and polarizing inflammatory cells, facilitating metabolic processes, stimulating angiogenesis and EMT, and increasing matrix metalloproteinase (MMP) and programmed cell death 1 ligand 1(PD-L1) expression (11, 18–20). The gene discussed is IL17A; the disease is neoplasm.